-
"Artificial red blood cells" are used in human trials for the first time! Or will revolutionize the treatment of patients with blood disorders!
Time of Update: 2023-01-06
The UK's National Health Service (NHS) has launched a clinical trial with research institutions such as the University of Bristol to inject laboratory-grown red blood cells into humans for the first time.
-
Yi Shuo Blood New Time and Space Gathering Chinese and foreign forces, talking about multidisciplinary progress, MM International Exchange Conference was grandly held
Time of Update: 2023-01-06
The content is rich and rewarding, I hope that all colleagues, especially young doctors, will ponder this repeatedly and move forward firmly!At the end of the conference, Professor Chen Wenming, the chairman of the conference, concluded that the conference showed the considerable results of clinical trials, and then sublimated to real-world patient data statistics, and explained in detail the treatment strategies of MM and the development of high-quality real-world research through Sino-foreign exchanges and interdisciplinary sharing.
-
Roche's "Blood Stars" shines in the Bo, gathering all parties to benefit Chinese blood disease patients
Time of Update: 2023-01-06
Professor Wu Depei, Chairman of the Hematology Society Branch of the Chinese Medical Association, pointed out: "Nowadays, the development of blood disease treatment is changing with each passing day, and innovative drugs are constantly emerging; The world's first CD79b-targeting antibody drug conjugate (ADC), vepotuzumab, which will be launched in China, is the biggest breakthrough in the field of lymphoma in the past 20 years and is expected to revolutionize the standard of clinical treatment.
-
Roche's "Blood Stars" shines in the Bo, gathering all parties to benefit Chinese blood disease patients
Time of Update: 2023-01-06
Professor Wu Depei, Chairman of the Hematology Society Branch of the Chinese Medical Association, pointed out: "Nowadays, the development of blood disease treatment is changing with each passing day, and innovative drugs are constantly emerging; The world's first CD79b-targeting antibody drug conjugate (ADC), vepotuzumab, which will be launched in China, is the biggest breakthrough in the field of lymphoma in the past 20 years and is expected to revolutionize the standard of clinical treatment.
-
【2022 ASH Field Frontier】Treatment status and stratified prognosis of multiple myeloma
Time of Update: 2023-01-06
Poster #4518The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma PatientsKey author: Hongying YouKey information: Clinically significant end-stage organ damage and high tumor burden in 1q21+ patients are independent high-risk cytogenetic factors for poor prognosis in patients with NDMM, where 4 or more copy numbers and major clone locations are significantly associated with prognosis.
-
【2022 ASH Field Frontier】Treatment status and stratified prognosis of multiple myeloma
Time of Update: 2023-01-06
Poster #4518The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma PatientsKey author: Hongying YouKey information: Clinically significant end-stage organ damage and high tumor burden in 1q21+ patients are independent high-risk cytogenetic factors for poor prognosis in patients with NDMM, where 4 or more copy numbers and major clone locations are significantly associated with prognosis.
-
Professor Cai Qingqing: New drugs continue to emerge, where is the treatment of relapsed and refractory diffuse large B-cell lymphoma? The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-06
CAR-TCAR-T is an effective option for patients with R/R DLLBL who have failed R-CHOP, are not suitable for transplantation, or have failed HDC-ASCT 。 Current CD19-targeting CAR-T cell products for DLBCL include Axicabtagene ciloleucel (Axi-cel, ZUMA-1 study), Tisagenlecleucel (Tisa-cel, JULIET study), and Lisocabtagene maraleucel (Liso-cel, TRANSCEND study), at R/R Higher treatment was shown in all third-line and above treatments for DLBCL: ORR of 52-83% and CR rate of 40% to 58%.
-
Professor Cai Qingqing: New drugs continue to emerge, where is the treatment of relapsed and refractory diffuse large B-cell lymphoma? The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-06
CAR-TCAR-T is an effective option for patients with R/R DLLBL who have failed R-CHOP, are not suitable for transplantation, or have failed HDC-ASCT 。 Current CD19-targeting CAR-T cell products for DLBCL include Axicabtagene ciloleucel (Axi-cel, ZUMA-1 study), Tisagenlecleucel (Tisa-cel, JULIET study), and Lisocabtagene maraleucel (Liso-cel, TRANSCEND study), at R/R Higher treatment was shown in all third-line and above treatments for DLBCL: ORR of 52-83% and CR rate of 40% to 58%.
-
Efficacy of Midostaurin in combination with intensive chemotherapy in young and elderly patients with AML with FLT3-ITD mutations
Time of Update: 2023-01-06
In a randomized Phase 3 pivotal CALGB 10603 (RATIFY) trial comparing placebo, patients aged 18 to 59 years with newly diagnosed AML with FLT3 mutation experienced significant improvements in overall survival (OS) and event-free survival (EFS) after receiving midostaurin plus intensive chemotherapy sequential 1-year midostaurin maintenance therapy.
-
Efficacy of Midostaurin in combination with intensive chemotherapy in young and elderly patients with AML with FLT3-ITD mutations
Time of Update: 2023-01-06
In a randomized Phase 3 pivotal CALGB 10603 (RATIFY) trial comparing placebo, patients aged 18 to 59 years with newly diagnosed AML with FLT3 mutation experienced significant improvements in overall survival (OS) and event-free survival (EFS) after receiving midostaurin plus intensive chemotherapy sequential 1-year midostaurin maintenance therapy.
-
Another gene therapy coming? FDA updates regulatory progress for hemophilia therapy
Time of Update: 2023-01-05
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec content team editorToday, BioMarin Pharmaceutical announced that it has been notified that the FDA no longer plans to hold an advisory committee meeting to discuss the Biologics License Application (BLA) for Roctavian (valoctocogene roxaparvovec).
-
Professor Gong Tiejun: Therapeutic progress of targeted therapy in young patients with acute myeloid leukemia The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-05
Recently, a number of new drug marketing applications on the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration have attracted much attention, so what are the exploration of targeted therapy in young AML patients?Professor Gong TiejunResearch progress on targeted drugs, including chimeric antigen receptor T cell (CAR-T) therapy, bispecific antibody drugs and antibody drug conjugates, focuses on lymphoma, myeloma and acute lymphoblastic leukemia.
-
Moving forward, leukemia and lymphoma special session 3 explores new progress in hematological tumors The Harbin branch of the 2022 CSCO Academic Annual Conference
Time of Update: 2023-01-05
Professor Qiu Lin and Professor Lai Yongrong presidedResults of a phase Ib/IIa clinical study of MIL62 injection combined with orelabrutinib tablets in the treatment of r/r B-NHLProfessor Shi Yuankai gave a wonderful reportProfessor Shi Yuankai from Cancer Hospital of Chinese Academy of Medical Sciences shared the results of a phase Ib/IIa clinical study evaluating the safety and efficacy of MIL62 injection combined with orelabrutinib tablets in the treatment of r/r B-NHL.
-
Micro-classroom No. 18 Professor Luo Jun: The latest exploration of MRD detection and application
Time of Update: 2023-01-05
Figure 3 Consistency between MS and NGS detectionThe 2022 EHA Conference also presented a study4 comparing the accuracy of NGF and functional imaging in MRD assessment and exploring the guiding significance of MRD in consolidation therapy.
-
【Lancet Haematol】Ponatinib and Belintoumab bring Ph+ ALL into deep remission, is there no need for transplantation?
Time of Update: 2023-01-05
Ph+ ALLNewly diagnosed Philadelphia chromosome-positive (Ph+) adult acute lymphoblastic leukemia (ALL) patients are treated with intensive chemotherapy plus TKI, followed by allogeneic hematopoietic s
-
I can't understand the blood coagulation results, and the eight modes are easy to get!
Time of Update: 2023-01-04
Mode 6: PT, APTT and TT are significantly elevated, FBG is low, DD is normal or elevated This mode, the most common cause is liver disease (such as cirrhosis), resulting in insufficient synthesis of various coagulation factors in the liver.
-
Cancer Med: the immune checkpoint gene VSIR predicts prognosis in patients with acute myeloid leukemia and myelodysplastic syndromes
Time of Update: 2023-01-04
Figure 4: VSIR expression in single cells associated with leukemiaFigure 5: Prognostic value of VSIR in other blood cancer types.
Figure 4: VSIR expression in single cells associated with leukemiaFigure 5: Prognostic value of VSIR in other blood cancer types.
-
Fifth edition of the WHO classification MDS and AML (Interpretation Update)
Time of Update: 2023-01-04
1. The name WHO-HAEM5 renamed myelodysplastic syndroms (MDS) as myelodysplastic neoplasms (MDN), the factors of the name change, one of which emphasizes that MDS is a tumor nature, The second is consistent with the naming of myeloproliferative tumors (MPNs).
-
Common causes of lymphocytosis or decrease [Note]
Time of Update: 2023-01-04
Pathological increase(1) infection:(2) Tumors:(3) Recovery period of acute infectious diseases(4) Transplant rejection:(5) Relative increase in lymphocyte ratio:3.
Reactive(1) infection:(2) Drug allergy(3)After blood transfusion, hemodialysis or cardiopulmonary bypass,(4)Others:
-
Everything you want to know about bevacizumab is here!
Time of Update: 2023-01-04
1. Applicable diseases Bevacizumab is a recombinant humanized monoclonal antibody that inhibits VEGF binding to its receptors by specifically targeting human vascular endothelial growth factor (VEGF), inhibits the formation of tumor blood vessels, reduces the supply of blood, oxygen and other nutrients to tumors, thereby inhibiting tumor cell growth.
